Atlas Trials

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Clinical trial NCT05493683 · UNKNOWN

Trial details

NCT number
NCT05493683
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Colorectal Neoplasms
Start date
2022-08-01
Primary completion
2025-07-01
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.